Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
HIV-Associated Lipodystrophy Syndrome
About this trial
This is an interventional treatment trial for HIV-Associated Lipodystrophy Syndrome focused on measuring HIV, Lipoatrophy, Lipodystrophy, Treatment Naive, HIV Infections, Hypercholesterolemia
Eligibility Criteria
Inclusion Criteria: Antiretroviral naïve patients HIV-1 infection as documented by a licensed HIV-1 antibody ELISA. Fulfilling the criteria for starting antiretroviral therapy. Ability to understand and provide written informed consent. Exclusion Criteria: Women being pregnant or breast-feeding. Fertile women using no safe contraception. Patients with active intravenous drug use. Abuse of alcohol, which in the opinion of the treating physician will reduce the patient´s ability to follow a therapeutic regimen and evaluations of the protocol. Ongoing medical treatment, which has a clinically significant interaction with lopinavir, ritonavir or efavirenz. Creatinine > 200 mmol/l. ALT or AST > 5 times upper normal value (200U/l).
Sites / Locations
- Department of Infectious Diseases, Hvidovre University Hospital
- Department of Infectious Diseases, Aalborg Hospital
- Department of Infectious Diseases, Aarhus University Hospital
- Department of Infectious Diseases, Rigshospitalet
- Department of Infectious Diseases, Odense University Hospital